Business
Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives
Seasoned industry professionals underpinned by newly strengthened balance sheet to drive key clinical programs AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS
About this update from Genprex, Inc.
[{"type":"text","content":"\nSeasoned industry professionals underpinned by newly strengthened balance sheet to drive key clinical programs \n\n AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGenprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Catherine M. Vaczy as Executive Vice President and Chief Strategy Officer and Michael T. Redman as Executive Vice President and Chief Operating Officer. These appointments follow on the heels of the Company’s Fast Track Designation for its lead drug candidate, its newly licensed gene therapy for diabetes and capital raise of over $26 million that will support funding its clinical programs. Both executives will play pivotal roles as the Company advances toward the start of new clinical trials later this year and pursues partnerships for the development of its gene therapies.\n\n\n“We are delighted to welcome Catherine and Michael to our executive leadership team. They join us at an exciting time as we advance our lead drug candidate into key clinical programs in non-small cell lung cancer and pursue partnership opportunities for our oncology platform and newly licensed gene therapy technology for diabetes,” said Rodney Varner, Chief Executive Officer of Genprex. “Catherine and Michael each have significant biotechnology company experience that enhances our capabilities and will be instrumental in advancing our programs. Their combined expertise in business development, corporate strategy, manufacturing, clinical trial strategy and operations and regulatory affairs will be of great value as we build Genprex into a leading gene therapy company bringing new treatment options to patients in need. We are fortunate to have raised over $26 million just prior to the current turmoil in the markets, significantly strengthening our balance sheet and well positioning us financially as we execute on our strategic plan.”\n\n\nMs. Vaczy has more than 20 years of experience as a founder and senior executive of life science companies, serving as a strategic partner and business and legal advisor to senior leadership teams and boards. Most recently, Ms. Vaczy has provided strategic advisory services to early stage biotechnology companies. In 2005, Ms. Vaczy co-fo...